2 weeks Ago By Defense World Staff
Bank of Montreal Can lessened its stake in NeurAxis, Inc. (NASDAQ:NRXS – Free Report) by 6.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission.
The institutional investor owned 139,017 shares of the company’s stock after selling 10,000 shares during the period. Bank of Montreal Can owned 1.94% of NeurAxis worth $327,000 at the end of the most recent quarter.
Separately, Parsons Capital Management Inc. RI raised its position in shares of NeurAxis by 797.9% during the fourth quarter.
Parsons Capital Management Inc. RI now owns 116,726 shares of the company’s stock worth $274,000 after purchasing an additional 103,726 shares during the period. Hedge funds and other institutional investors own 11.
77% of the company’s stock. NeurAxis Stock Up 24.8 %Shares of NASDAQ:NRXS opened at $2.
43 on Thursday. The company’s fifty day moving average is $2.07 and its two-hundred day moving average is $2.
50. The company has a market cap of $17.56 million, a P/E ratio of -1.
32 and a beta of 3.46. NeurAxis, Inc.
has a 12-month low of $1.33 and a 12-month high of $3.78.
Insider Activity at NeurAxisIn other news, major shareholder Brian Hannasch acquired 18,065 shares of the company’s stock in a transaction that occurred on Monday, April 21st. The shares were purchased at an average price of $1.73 per share, for a total transaction of $31,252.
45. Following the completion of the acquisition, the insider now owns 775,966 shares of the company’s stock, valued at approximately $1,342,421.18.
This represents a 2.38 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
15.20% of the stock is currently owned by insiders. NeurAxis Profile (Free Report)NeurAxis, Inc, a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome.Featured ArticlesFive stocks we like better than NeurAxisWhat is the Dow Jones Industrial Average (DJIA)?Can IBM’s Q1 Earnings Spark a Breakout for the Stock?Are Penny Stocks a Good Fit for Your Portfolio?S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?What Are Trending Stocks? Trending Stocks ExplainedFundamentally Sound, These 5 Stocks Sold Off Anyway.
